🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11986517

    Cancer vaccines targeting mesothelin and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11981662

    Pyrazole derivatives with anticancer activity

    The Board of Regents of the University of Texas System · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11980633

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11981752

    Tumor associated monocyte/macrophage binding peptide and methods of use thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11976274

    Methods and compositions for identifying neoantigens for use in treating and preventing cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11975106

    Uses of halogenated xanthenes in oncology and virology

    Provectus Pharmatech, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11975028

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11976299

    Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11971410

    Methods of classifying response to immunotherapy for cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11969444

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11969499

    Hydrogel delivery of sting immunotherapy for treatment cancer

    The Board of Regents of the University of Texas System · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11965161

    Methods and compositions for sensitization of tumor cells to immune therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11964000

    Cancer treatment methods using nanofiber stabilized growth factors

    Northwestern University · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11964021

    Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

    EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11964985

    Anti-cancer compounds targeting Ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11963958

    RET inhibitor for use in treating cancer having a RET alteration

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Cardiff Oncology, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11952364

    TRK inhibitors useful as anticancer drugs

    TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11951124

    Tellurium nanowires with anticancer properties synthesized by green chemistry

    Northwestern University · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11952429

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11952419

    Reagents and methods for treating cancer and autoimmune disease

    UNIVERSITY OF CONNECTICUT · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11944627

    Methods for treating hematological malignancies and Ewing's sarcoma

    Kura Oncology, Inc. · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11946049

    tRNA/pre-miRNA compositions and use in treating cancer

    The Regents of the University of California · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11939596

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11938124

    Combination therapy for treatment of cancer

    PMV PHARMACEUTICALS, INC. · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11932606

    Anti-cancer/anti-fibrosis compounds

    The Regents of the University of California · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11932692

    Methods of treating cancer pain by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11926668

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11925629

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11925663

    Methods of managing tumor flare in adoptive immunotherapy

    Atara Biotherapeutics, Inc. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11918660

    Viral vectors for cancer therapy

    Krystal Biotech, Inc. · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11918686

    Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents

    The Regents of the University of California · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11912758

    Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel

    The Board of Regents of the University of Texas System · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11911367

    Methods for treating cancer

    Regents of the University of Minnesota · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11905268

    Anthranilic acid derivatives and their use in the treatment of human cancers

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11896558

    Use of an RXR agonist and taxanes in treating Her2+ cancers

    The Board of Regents of the University of Texas System · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11891399

    Inhibitors of cancer invasion, attachment, and/or metastasis

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11891402

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11883492

    Combination treatment of chemoresistant cancers

    The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11883468

    Compositions and methods to suppress tumor growth in bone, prevent cachectic muscle loss, and preserve skeletal integrity

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11883420

    Sting agonists for treating bladder cancer and solid tumors

    VENENUM BIODESIGN, LLC · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11878961

    Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer

    The Board of Regents of the University of Texas System · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11879017

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11872092

    Methods for surgical guidance in breast cancer surgery and lymph node dissection using two or more implantation devices comprising a capsule and a population of ultrasound-switchable fluorophores incorporated in the capsule

    The Board of Regents of the University of Texas System · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11865157

    Compositions and methods of targeting cancer stem cells

    The Board of Regents of the University of Texas System · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11865140

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11866688

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.